Role of adiponectin in obesity related gastrointestinal carcinogenesis

Cytokine and Growth Factor Reviews

Volumn 26, Issue 1, 2015, Pages 83-93

  Nagaraju, Ganji Purnachandra ^a   Aliya, Sheik ^b   Alese, Olatunji Boladale ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY   (India)

Author keywords

Adiponectin; Gastrointestinal carcinogenesis; Inflammation; Obesity; Signaling pathways

Indexed keywords

ADENYLATE KINASE; ADIPONECTIN; ADIPONECTIN RECEPTOR 1; ADIPONECTIN RECEPTOR 2; ADP 355; AMG 131; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; LEPTIN; MITOGEN ACTIVATED PROTEIN KINASE P38; NITRIC OXIDE SYNTHASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; SOMATOMEDIN C; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ADIPONECTIN RECEPTOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BIOCHEMISTRY; CARCINOGENESIS; CELL CYCLE ARREST; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL CANCER; CYTOKINE PRODUCTION; DIGESTIVE SYSTEM CANCER; DISEASE ASSOCIATION; ESOPHAGUS CANCER; GENE MUTATION; HUMAN; INFLAMMATION; LIVER CANCER; MOLECULAR MECHANICS; NONHUMAN; OBESITY; PANCREAS CANCER; REVIEW; SIGNAL TRANSDUCTION; STOMACH CANCER; TUMOR GROWTH; ANIMAL; BLOOD; COMPLICATION; GASTROINTESTINAL NEOPLASMS; GENETICS; METABOLISM; MOUSE; WHITE ADIPOSE TISSUE;

ADIPONECTIN; ADIPOSE TISSUE, WHITE; ANIMALS; CARCINOGENESIS; GASTROINTESTINAL NEOPLASMS; HUMANS; MICE; OBESITY; RECEPTORS, ADIPONECTIN; SIGNAL TRANSDUCTION;

EID: 84926675511     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2014.06.007     Document Type: Review

References (145)

1. van Kruijsdijk R.C., van der Wall E., Visseren F.L. Obesity and cancer: the role of dysfunctional adipose tissue. Cancer Epidemiol Biomarkers Prev 2009, 18:2569-2578.
2. Kelesidis I., Kelesidis T., Mantzoros C. Adiponectin and cancer: a systematic review. Br J Cancer 2006, 94:1221-1225.
3. Wolk A., Gridley G., Svensson M., Nyrén O., McLaughlin J.K., Fraumeni J.F., et al. A prospective study of obesity and cancer risk (Sweden). Cancer Causes Control 2001, 12:13-21.
4. Larsson S.C., Rutegård J., Bergkvist L., Wolk A. Physical activity, obesity, and risk of colon and rectal cancer in a cohort of Swedish men. Eur J Cancer 2006, 42:2590-2597.
5. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63:11-30.
6. Pera M., Manterola C., Vidal O., Grande L. Epidemiology of esophageal adenocarcinoma. J Surg Oncol 2005, 92:151-159.
7. El-Serag H.B., Rudolph K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132:2557-2576.
8. Bianchini F., Kaaks R., Vainio H. Overweight, obesity, and cancer risk. Lancet Oncol 2002, 3:565-574.
9. Donohoe C., Pidgeon G., Lysaght J., Reynolds J. Obesity and gastrointestinal cancer. Br J Surg 2010, 97:628-642.
10. Stolzenberg-Solomon R.Z., Schairer C., Moore S., Hollenbeck A., Silverman D.T. Lifetime adiposity and risk of pancreatic cancer in the NIH-AARP Diet and Health Study cohort. Am J Clin Nutr 2013, 98:1057-1065.
11. Perrimon N., Pitsouli C., Shilo B.-Z. Signaling mechanisms controlling cell fate and embryonic patterning. Cold Spring Harb Perspect Biol 2012, 4:a005975.
12. Balmer M.L., Dufour J.-F. Molecular mechanisms of liver cancer metastasis. Mol Aspects Hepatocell Carcinoma 2012, 86.
13. Cardoso J., Boer J., Morreau H., Fodde R. Expression and genomic profiling of colorectal cancer. Biochim Biophys Acta (BBA) Rev Cancer 2007, 1775:103-137.
14. Osaki M., Oshimura Ma Ito H. PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 2004, 9:667-676.
15. Barb D., Williams C.J., Neuwirth A.K., Mantzoros C.S. Adiponectin in relation to malignancies: a review of existing basic research and clinical evidence. Am J Clin Nutr 2007, 86:66S-858S.
16. Huang X.F., Chen J.Z. Obesity, the PI3K/Akt signal pathway and colon cancer. Obes Rev 2009, 10:610-616.
17. Michl P., Downward J. Mechanisms of disease: PI3K/AKT signaling in gastrointestinal cancers. Z Gastroenterol 2005, 43:1133-1139.
18. Nakano Y., Tobe T., Choi-Miura N.-H., Mazda T., Tomita M. Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem 1996, 120:803-812.
19. Chandran M., Phillips S.A., Ciaraldi T., Henry R.R. Adiponectin: more than just another fat cell hormone. Diabetes Care 2003, 26:2442-2450.
20. Scherer P.E., Williams S., Fogliano M., Baldini G., Lodish H.F. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995, 270:26746-26749.
21. Salani B., Briatore L., Andraghetti G., Adami G.F., Maggi D., Cordera R. High-molecular weight adiponectin isoforms increase after biliopancreatic diversion in obese subjects. Obesity 2006, 14:1511-1514.
22. Xu A., Chan K.W., Hoo R.L., Wang Y., Tan K.C., Zhang J., et al. Testosterone selectively reduces the high molecular weight form of adiponectin by inhibiting its secretion from adipocytes. J Biol Chem 2005, 280:18073-18080.
23. Wolf A.M., Wolf D., Rumpold H., Enrich B., Tilg H. Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem Biophys Res Commun 2004, 323:630-635.
24. Wozniak S.E., Gee L.L., Wachtel M.S., Frezza E.E. Adipose tissue: the new endocrine organ? A review article. Dig Dis Sci 2009, 54:1847-1856.
25. Phelip J.M., Bageacu S., Baconnier M., Barabino G., Del Tedesco E., Benhamou P.Y., et al. Comparison of adiponectin concentration between pancreatic cancer and colorectal cancer. J Gastrointest Oncol 2011, 2:232.
26. Rosen E., Eguchi J., Xu Z. Transcriptional targets in adipocyte biology. Expert Opin Ther Targets 2009, 13:975-986.
27. Simpson F., Whitehead J.P. Adiponectin-it's all about the modifications. Int J Biochem Cell Biol 2010, 42:785-788.
28. Ishikawa M., Kitayama J., Yamauchi T., Kadowaki T., Maki T., Miyato H., et al. Adiponectin inhibits the growth and peritoneal metastasis of gastric cancer through its specific membrane receptors AdipoR1 and AdipoR2. Cancer Sci 2007, 98:1120-1127.
29. Hursting S.D., Lashinger L.M., Wheatley K.W., Rogers C.J., Colbert L.H., Nunez N.P., et al. Reducing the weight of cancer: mechanistic targets for breaking the obesity-carcinogenesis link. Best Pract Res Clin Endocrinol Metab 2008, 22:659-669.
30. Jardé T., Perrier S., Vasson M.-P., Caldefie-Chézet F. Molecular mechanisms of leptin and adiponectin in breast cancer. Eur J Cancer 2011, 47:33-43.
31. Shetty S., Kusminski C.M., Scherer P.E. Adiponectin in health and disease: evaluation of adiponectin-targeted drug development strategies. Trends Pharmacol Sci 2009, 30:234-239.
32. Kadowaki T, Yamauchi T, Nagai R, Kamon J. Adiponectin receptor and gene encoding the same. Google Patents; 2011.
33. Whitehead J., Richards A., Hickman I., Macdonald G., Prins J. Adiponectin - a key adipokine in the metabolic syndrome. Diabetes Obes Metab 2006, 8:264-280.
34. Zimmermann R., Strauss J.G., Haemmerle G., Schoiswohl G., Birner-Gruenberger R., Riederer M., et al. Fat mobilization in adipose tissue is promoted by adipose triglyceride lipase. Science 2004, 306:1383-1386.
35. Goldstein B.J., Scalia R. Adiponectin: a novel adipokine linking adipocytes and vascular function. J Clin Endocrinol Metab 2004, 89:2563-2568.
36. Tsuchida A., Yamauchi T., Ito Y., Hada Y., Maki T., Takekawa S., et al. Insulin/Foxo1 pathway regulates expression levels of adiponectin receptors and adiponectin sensitivity. J Biol Chem 2004, 279:30817-30822.
37. Hug C., Wang J., Ahmad N.S., Bogan J.S., Tsao T.-S., Lodish H.F. T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proc Natl Acad Sci U S A 2004, 101:10308-10313.
38. Ernst P.B., Gold B.D. The disease spectrum of Helicobacter pylori: the immunopathogenesis of gastroduodenal ulcer and gastric cancer. Annu Rev Microbiol 2000, 54:615-640.
39. Tilg H., Moschen A.R. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006, 6:772-783.
40. Mustafa M., Mustafa A., Nyberg F., Mangat H., Elhassan A., Winblad B., et al. Hypophysectomy enhances interleukin-1beta, tumor necrosis factor-alpha, and interleukin-10 mRNA expression in the rat brain. J Interferon Cytokine Res 1999, 19:583-587.
41. Calabro P., Chang D.W., Willerson J.T., Yeh E.T. Release of C-reactive protein in response to inflammatory cytokines by human adipocytes: linking obesity to vascular inflammation. J Am Coll Cardiol 2005, 46:1112-1113.
42. Tilg H., Vannier E., Vachino G., Dinarello C., Mier J. Antiinflammatory properties of hepatic acute phase proteins: preferential induction of interleukin 1 (IL-1) receptor antagonist over IL-1 beta synthesis by human peripheral blood mononuclear cells. J Exp Med 1993, 178:1629-1636.
43. Asseman C., Mauze S., Leach M.W., Coffman R.L., Powrie F. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med 1999, 190:995-1004.
44. He G., Karin M. NF-κB and STAT3 - key players in liver inflammation and cancer. Cell Res 2010, 21:159-168.
45. Roshanaei-Moghaddam B., Katon W.J., Russo J. The longitudinal effects of depression on physical activity. Gen Hosp Psychiatry 2009, 31:306-315.
46. Li L., Wu L.-L. Adiponectin and interleukin-6 in inflammation-associated disease. Vitam Horm 2012, 90:375-395.
47. Gil A., Aguilera C.M., Gil-Campos M., Canete R. Altered signalling and gene expression associated with the immune system and the inflammatory response in obesity. Br J Nutr 2007, 98:S6-S121.
48. Tsao T.-S., Tomas E., Murrey H.E., Hug C., Lee D.H., Ruderman N.B., et al. Role of disulfide bonds in Acrp30/adiponectin structure and signaling specificity different oligomers activate different signal transduction pathways. J Biol Chem 2003, 278:50810-50817.
49. Reuter S., Gupta S.C., Chaturvedi M.M., Aggarwal B.B. Oxidative stress, inflammation, and cancer: how are they linked. Free Radic Biol Med 2010, 49:1603-1616.
50. Nagaraju G.P., Nalla A.K., Gupta R., Mohanam S., Gujrati M., Dinh D.H., et al. siRNA-mediated downregulation of MMP-9 and uPAR in combination with radiation induces G2/M cell-cycle arrest in Medulloblastoma. Mol Cancer Res 2011, 9:51-66.
51. Wang R.A., Li Q.L., Li Z.S., Zheng P.J., Zhang H.Z., Huang X.F., et al. Apoptosis drives cancer cells proliferate and metastasize. J Cell Mol Med 2013, 17:205-211.
52. Green D.R. Apoptotic pathways: the roads to ruin. Cell 1998, 94:695-698.
53. Holler N., Zaru R., Micheau O., Thome M., Attinger A., Valitutti S., et al. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat Immunol 2000, 1:489-495.
54. Fulda S., Debatin K. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006, 25:4798-4811.
55. Wang X., Martindale J., Liu Y., Holbrook N. The cellular response to oxidative stress: influences of mitogen-activated protein kinase signalling pathways on cell survival. Biochem J 1998, 333:291-300.
56. Plummer S.M., Holloway K.A., Manson M.M., Munks R.J., Kaptein A., Farrow S., et al. Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kB activation via the NIK/IKK signalling complex. Oncogene 1999, 18:6013-6020.
57. Chandrasekar B., Mummidi S., Perla R., Bysani S., Dulin N., Liu F., et al. Fractalkine (CX3CL1) stimulated by nuclear factor kappaB (NF-kappaB)-dependent inflammatory signals induces aortic smooth muscle cell proliferation through an autocrine pathway. Biochem J 2003, 373:547-558.
58. Brand S., Dambacher J., Beigel F., Olszak T., Diebold J., Otte J.-M., et al. CXCR4 and CXCL12 are inversely expressed in colorectal cancer cells and modulate cancer cell migration, invasion and MMP-9 activation. Exp Cell Res 2005, 310:117-130.
59. Ferrante A. Obesity-induced inflammation: a metabolic dialogue in the language of inflammation. J Intern Med 2007, 262:408-414.
60. Nagaraju G.P., Zhu S., Wen J., Farris A.B., Adsay V.N., Diaz R., et al. Novel synthetic curcumin analogues EF31 and UBS109 are potent DNA hypomethylating agents in pancreatic cancer. Cancer Lett 2013, 341:195-203.
61. Yu H., Pardoll D., Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009, 9:798-809.
62. Oren M., Damalas A., Gottlieb T., Michael D., Taplick J., Leal J.F., et al. Regulation of p53. Ann NY Acad Sci 2002, 973:374-383.
63. Roos W.P., Kaina B. DNA damage-induced cell death by apoptosis. Trends Mol Med 2006, 12:440-450.
64. Rose D.P., Royak-Schaler R. Tumor biology and prognosis in black breast cancer patients: a review. Cancer Detect Prev 2001, 25:16.
65. O'Connell J., O'Sullivan G.C., Collins J.K., Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996, 184:1075-1082.
66. Gross A., McDonnell J.M., Korsmeyer S.J. BCL-2 family members and the mitochondria in apoptosis. Genes Dev 1999, 13:1899-1911.
67. E.L-Baz H.A., Tamer E.M., Elabd E.M., Ramadan A., Elharoun A.S., Elmorsy E.A., et al. Serum adiponectin and resistin levels in de novo and relapsed acute lymphoblastic leukemia children patients. Iran J Public Health 2013, 42:504-510.
68. Nishihara T., Baba M., Matsuda M., Inoue M., Nishizawa Y., Fukuhara A., et al. Adiponectin deficiency enhances colorectal carcinogenesis and liver tumor formation induced by azoxymethane in mice. World J Gastroenterol 2008, 14:6473.
69. Burnat G., Konturek P. 898 procarcinogenic effect of bile salts on Barrett's esophagus is mediated by increased activity of NfκB. Gastroenterology 2008, 134:A-129.
70. Whiteman D.C., Sadeghi S., Pandeya N., Smithers B.M., Gotley D.C., Bain C.J., et al. Combined effects of obesity, acid reflux and smoking on the risk of adenocarcinomas of the oesophagus. Gut 2008, 57:173-180.
71. Konturek P.C., Burnat G., Rau T., Hahn E.G., Konturek S. Effect of adiponectin and ghrelin on apoptosis of Barrett adenocarcinoma cell line. Dig Dis Sci 2008, 53:597-605.
72. Kadowaki T., Yamauchi T., Kubota N., Hara K., Ueki K., Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006, 116:1784-1792.
73. Howard J., Beddy P., Ennis D., Keogan M., Pidgeon G., Reynolds J. Associations between leptin and adiponectin receptor upregulation, visceral obesity and tumour stage in oesophageal and junctional adenocarcinoma. Br J Surg 2010, 97:1020-1027.
74. Akiyama T., Yoneda M., Maeda S., Nakajima A., Koyama S., Inamori M. Visceral obesity and the risk of Barrett's esophagus. Digestion 2011, 83:142-145.
75. Reid B., Barrett M., Galipeau P., Sanchez C., Neshat K., Cowan D., et al. Barrett's esophagus: ordering the events that lead to cancer. Eur J Cancer Prev 1996, 5:57-65.
76. Brown L.M., Swanson C.A., Gridley G., Swanson G.M., Schoenberg J.B., Greenberg R.S., et al. Adenocarcinoma of the esophagus: role of obesity and diet. J Natl Cancer Inst 1995, 87:104-109.
77. Rubenstein J.H., Dahlkemper A., Kao J.Y., Zhang M., Morgenstern H., McMahon L., et al. A pilot study of the association of low plasma adiponectin and Barrett's esophagus. Am J Gastroenterol 2008, 103:1358-1364.
78. Yildirim A., Bilici M., Çayir K., Yanmaz V., Yildirim S., Tekin S.B. Serum adiponectin levels in patients with esophageal cancer. Jpn J Clin Oncol 2009, 39:92-96.
79. Rubenstein J.H., Kao J.Y., Madanick R.D., Zhang M., Wang M., Spacek M.B., et al. Association of adiponectin multimers with Barrett's oesophagus. Gut 2009, 58:1583-1589.
80. Nagaraju G.P.C., Sharma D. Anti-cancer role of SPARC, an inhibitor of adipogenesis. Cancer Treat Rev 2011, 37:559-566.
81. Clement G., Braunschweig R., Pasquier N., Bosman F., Benhattar J. Alterations of the Wnt signaling pathway during the neoplastic progression of Barrett's esophagus. Oncogene 2006, 25:3084-3092.
82. Bani-Hani K., Martin I.G., Hardie L.J., Mapstone N., Briggs J.A., Forman D., et al. Prospective study of cyclin D1 overexpression in Barrett's esophagus: association with increased risk of adenocarcinoma. J Natl Cancer Inst 2000, 92:1316-1321.
83. Reid B.J., Blount P.L., Rabinovitch P.S. Biomarkers in Barrett's esophagus. Gastrointest Endosc Clin N Am 2003, 13:369-397.
84. Ogunwobi O., Beales I. Leptin stimulates the proliferation of human oesophageal adenocarcinoma cells via HB-EGF and TGFa mediated transactivation of the epidermal growth factor receptor. Br J Biomed Sci 2008, 65:121-127.
85. Beales I.L., Garcia-Morales C., Ogunwobi O.O., Mutungi G. Adiponectin inhibits leptin-induced oncogenic signalling in oesophageal cancer cells by activation of PTP1B. Mol Cell Endocrinol 2014, 382:150-158.
86. Dvorakova K., Payne C.M., Ramsey L., Holubec H., Sampliner R., Dominguez J., et al. Increased expression and secretion of interleukin-6 in patients with Barrett's esophagus. Clin Cancer Res 2004, 10:2020-2028.
87. Zhang R., Wu J., Liu D., Shan H., Zhang J. Anti-inflammatory effect of full-length adiponectin and proinflammatory effect of globular adiponectin in esophageal adenocarcinoma cells. Oncol Res Featur Preclin Clin Cancer Ther 2013, 21:15-21.
88. Monto A., Alonzo J., Watson J.J., Grunfeld C., Wright T.L. Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. Hepatology 2002, 36:729-736.
89. Powell E.E., Jonsson J.R., Clouston A.D. Steatosis: co-factor in other liver diseases. Hepatology 2005, 42:5-13.
90. Jonsson J.R., Barrie H.D., O'Rourke P., Clouston A.D., Powell E.E. Obesity and steatosis influence serum and hepatic inflammatory markers in chronic hepatitis C. Hepatology 2008, 48:80-87.
91. Hung C.-H., Wang J.-H., Hu T.-H., Chen C.-H., Chang K.-C., Yen Y.-H., et al. Insulin resistance is associated with hepatocellular carcinoma in chronic hepatitis C infection. World J Gastroenterol 2010, 16:2265.
92. Chen M.J., Yeh Y.T., Lee K.T., Tsai C.J., Lee H.H., Wang S.N. The promoting effect of adiponectin in hepatocellular carcinoma. J Surg Oncol 2012, 106:181-187.
93. Kotani K., Wakai K., Shibata A., Fujita Y., Ogimoto I., Naito M., et al. Serum adiponectin multimer complexes and liver cancer risk in a large cohort study in Japan. Asian Pac J Cancer Prev 2009, 10:87-90.
94. Adachi M., Brenner D.A. High molecular weight adiponectin inhibits proliferation of hepatic stellate cells via activation of adenosine monophosphate-activated protein kinase. Hepatology 2008, 47:677-685.
95. Sharma D., Wang J., Fu P.P., Sharma S., Nagalingam A., Mells J., et al. Adiponectin antagonizes the oncogenic actions of leptin in hepatocellular carcinogenesis. Hepatology 2010, 52:1713-1722.
96. Saxena N.K., Fu P.P., Nagalingam A., Wang J., Handy J., Cohen C., et al. Adiponectin modulates C-jun N-terminal kinase and mammalian target of rapamycin and inhibits hepatocellular carcinoma. Gastroenterology 2010, 139:1762-1773. e5.
97. Man K., Ng K.T., Xu A., Cheng Q., Lo C.M., Xiao J.W., et al. Suppression of liver tumor growth and metastasis by adiponectin in nude mice through inhibition of tumor angiogenesis and downregulation of Rho kinase/IFN-inducible protein 10/matrix metalloproteinase 9 signaling. Clin Cancer Res 2010, 16:967-977.
98. Page J.M., Harrison S.A. Nash and HCC. Clin Liver Dis 2009, 13:631-647.
99. Asano T., Watanabe K., Kubota N., Gunji T., Omata M., Kadowaki T., et al. Adiponectin knockout mice on high fat diet develop fibrosing steatohepatitis. J Gastroenterol Hepatol 2009, 24:1669-1676.
100. Bråkenhielm E., Veitonmäki N., Cao R., Kihara S., Matsuzawa Y., Zhivotovsky B., et al. Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci U S A 2004, 101:2476-2481.
101. Maeda N., Shimomura I., Kishida K., Nishizawa H., Matsuda M., Nagaretani H., et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 2002, 8:731-737.
102. Argilés J.M., Busquets S., Moore-Carrasco R., López-Soriano F.J. The role of cytokines in cancer cachexia. Cachexia and wasting: a modern approach 2006, 467-475. Springer.
103. Tsukada T., Fushida S., Harada S., Terai S., Yagi Y., Kinoshita J., et al. Adiponectin receptor-1 expression is associated with good prognosis in gastric cancer. J Exp Clin Cancer Res 2011, 30:1-12.
104. Yamamoto H., Maeda K., Uji Y., Tsuchihashi H., Mori T., Shimizu T., et al. Association between reduction of plasma adiponectin levels and risk of bacterial infection after gastric cancer surgery. PLOS ONE 2013, 8:e56129.
105. Yamauchi T., Iwabu M., Okada-Iwabu M., Kadowaki T. Adiponectin receptors: a review of their structure, function and how they work. Best Pract Res Clin Endocrinol Metab 2014, 28:15-23.
106. Otani K., Kitayama J., Yasuda K., Nio Y., Iwabu M., Okudaira S., et al. Adiponectin suppresses tumorigenesis in ApcMin/+ mice. Cancer Lett 2010, 288:177-182.
107. Ishikawa M., Kitayama J., Kazama S., Hiramatsu T., Hatano K., Nagawa H. Plasma adiponectin and gastric cancer. Clin Cancer Res 2005, 11:466-472.
108. Dalamaga M., Migdalis I., Fargnoli J.L., Papadavid E., Bloom E., Mitsiades N., et al. Pancreatic cancer expresses adiponectin receptors and is associated with hypoleptinemia and hyperadiponectinemia: a case-control study. Cancer Causes Control 2009, 20:625-633.
109. Larsson S.C., Orsini N., Wolk A. Body mass index and pancreatic cancer risk: a meta-analysis of prospective studies. Int J Cancer 2007, 120:1993-1998.
110. Zyromski N.J., Mathur A., Pitt H.A., Wade T.E., Wang S., Nakshatri P., et al. Obesity potentiates the growth and dissemination of pancreatic cancer. Surgery 2009, 146:258-263.
111. Pezzilli R., Zerbi A., Di Carlo V., Bassi C., Delle Fave G. Practical guidelines for acute pancreatitis. Pancreatology 2010, 10:523-535.
112. Bao Y., Giovannucci E.L., Kraft P., Stampfer M.J., Ogino S., Ma J., et al. A prospective study of plasma adiponectin and pancreatic cancer risk in five US cohorts. J Natl Cancer Inst 2013, 105:95-103.
113. Grote V.A., Rohrmann S., Dossus L., Nieters A., Halkjaer J., Tjønneland A., et al. The association of circulating adiponectin levels with pancreatic cancer risk: a study within the prospective EPIC cohort. Int J Cancer 2012, 130:2428-2437.
114. Chang M.-C., Chang Y.-T., Tien Y.-W., Liang P.-C., Jan I.-S., Wei S.-C., et al. T-cell regulatory gene CTLA-4 polymorphism/haplotype association with autoimmune pancreatitis. Clin Chem 2007, 53:1700-1705.
115. Dolcet X., Llobet D., Pallares J., Matias-Guiu X. NF-kB in development and progression of human cancer. Virchows Arch 2005, 446:475-482.
116. Kaklamani V.G., Wisinski K.B., Sadim M., Gulden C., Do A., Offit K., et al. Variants of the adiponectin (ADIPOQ) and adiponectin receptor 1 (ADIPOR1) genes and colorectal cancer risk. JAMA 2008, 300:1523-1531.
117. Vetvik K.K., Sonerud T., Lindeberg M., Lüders T., Størkson R.H., Jonsdottir K., et al. Globular adiponectin and its downstream target genes are up-regulated locally in human colorectal tumors: ex vivo and in vitro studies. Metabolism 2014, 63:672-681.
118. Hiyoshi M., Tsuno N.H., Otani K., Kawai K., Nishikawa T., Shuno Y., et al. Adiponectin receptor 2 is negatively associated with lymph node metastasis of colorectal cancer. Oncol Lett 2012, 3:756.
119. Ferroni P., Palmirotta R., Spila A., Martini F., Raparelli V., Fossile E., et al. Prognostic significance of adiponectin levels in non-metastatic colorectal cancer. Anticancer Res 2007, 27:483-489.
120. Wei E.K., Giovannucci E., Fuchs C.S., Willett W.C., Mantzoros C.S. Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst 2005, 97:1688-1694.
121. Song M., Zhang X., Wu K., Ogino S., Fuchs C.S., Giovannucci E.L., et al. Plasma adiponectin and soluble leptin receptor and risk of colorectal cancer: a prospective study. Cancer Prev Res 2013, 6:875-885.
122. Yamaji T., Iwasaki M., Sasazuki S., Tsugane S. Interaction between adiponectin and leptin influences the risk of colorectal adenoma. Cancer Res 2010, 70:5430-5437.
123. Fasshauer M., Paschke R. Regulation of adipocytokines and insulin resistance. Diabetologia 2003, 46:1594-1603.
124. Calle E.E., Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004, 4:579-591.
125. Chen M.-W., Ye S., Zhao L.-L., Wang S.-Y., Li Y.-X., Yu C.-J., et al. Association of plasma total and high-molecular-weight adiponectin with risk of colorectal cancer: an observational study in Chinese male. Med Oncol 2012, 29:3129-3135.
126. Sugiyama M., Takahashi H., Hosono K., Endo H., Kato S., Yoneda K., et al. Adiponectin inhibits colorectal cancer cell growth through the AMPK/mTOR pathway. Int J Oncol 2009, 34:339-344.
127. Yoneda K., Tomimoto A., Endo H., Iida H., Sugiyama M., Takahashi H., et al. Expression of adiponectin receptors, AdipoR1 and AdipoR2, in normal colon epithelium and colon cancer tissue. Oncol Rep 2008, 20:479-483.
128. Gunter M.J., Leitzmann M.F. Obesity and colorectal cancer: epidemiology, mechanisms and candidate genes. J Nutr Biochem 2006, 17:145-156.
129. Wasan H.S., Novelli M., Bee J., Bodmer W.F. Dietary fat influences on polyp phenotype in multiple intestinal neoplasia mice. Proc Natl Acad Sci U S A 1997, 94:3308-3313.
130. Wellen K.E., Thompson C.B. Cellular metabolic stress: considering how cells respond to nutrient excess. Mol Cell 2010, 40:323-332.
131. Fenton J.I., Birmingham J.M., Hursting S.D., Hord N.G. Adiponectin blocks multiple signaling cascades associated with leptin-induced cell proliferation in ApcMin/+ colon epithelial cells. Int J Cancer 2008, 122:2437-2445.
132. Williams C.J., Mitsiades N., Sozopoulos E., Hsi A., Wolk A., Nifli A.-P., et al. Adiponectin receptor expression is elevated in colorectal carcinomas but not in gastrointestinal stromal tumors. Endocr-Relat Cancer 2008, 15:289-299.
133. An W., Bai Y., Deng S.-X., Gao J., Ben Q.-W., Cai Q.-C., et al. Adiponectin levels in patients with colorectal cancer and adenoma: a meta-analysis. Eur J Cancer Prev 2012, 21:126-133.
134. Endo H., Hosono K., Fujisawa T., Takahashi H., Sugiyama M., Yoneda K., et al. Involvement of JNK pathway in the promotion of the early stage of colorectal carcinogenesis under high-fat dietary conditions. Gut 2009, 58:1637-1643.
135. Mutoh M., Teraoka N., Takasu S., Takahashi M., Onuma K., Yamamoto M., et al. Loss of adiponectin promotes intestinal carcinogenesis in min and wild-type mice. Gastroenterology 2011, 140:2000-2008. e2.
136. Fang J.Y., Richardson B.C. The MAPK signalling pathways and colorectal cancer. Lancet Oncol 2005, 6:322-327.
137. Tilg H., Kaser A. Adiponectin and JNK: metabolic/inflammatory pathways affecting gastrointestinal carcinogenesis. Gut 2009, 58:1576-1577.
138. Saxena A., Chumanevich A., Fletcher E., Larsen B., Lattwein K., Kaur K., et al. Adiponectin deficiency: role in chronic inflammation induced colon cancer. Biochim Biophys Acta (BBA) Mol Basis Dis 2012, 1822:527-536.
139. Kim A.Y., Lee Y.S., Kim K.H., Lee J.H., Lee H.K., Jang S.-H., et al. Adiponectin represses colon cancer cell proliferation via AdipoR1-and-R2-mediated AMPK activation. Mol Endocrinol 2010, 24:1441-1452.
140. Moon H.-S., Liu X., Nagel J.M., Chamberland J.P., Diakopoulos K.N., Brinkoetter M.T., et al. Salutary effects of adiponectin on colon cancer: in vivo and in vitro studies in mice. Gut 2013, 62:561-570.
141. Dalamaga M., Diakopoulos K.N., Mantzoros C.S. The role of adiponectin in cancer: a review of current evidence. Endocr Rev 2012, 33:547-594.
142. Otvos L., Haspinger E., La Russa F., Maspero F., Graziano P., Kovalszky I., et al. Design and development of a peptide-based adiponectin receptor agonist for cancer treatment. BMC Biotechnol 2011, 11:90.
143. Delort L., Jardé T., Dubois V., Vasson M.-P., Caldefie-Chézet F. New insights into anticarcinogenic properties of adiponectin: a potential therapeutic approach in breast cancer. Vitam Horm 2012, 90:397-417.
144. Higgins L.S., DePaoli A.M. Selective peroxisome proliferator-activated receptor γ(PPARγ) modulation as a strategy for safer therapeutic PPARγ activation. Am J Clin Nutr 2010, 91:72S-267S.
145. Fowler J.A., Lwin S.T., Drake M.T., Edwards J.R., Kyle R.A., Mundy G.R., et al. Host-derived adiponectin is tumor-suppressive and a novel therapeutic target for multiple myeloma and the associated bone disease. Blood 2011, 118:5872-5882.